Hec1 (highly expressed in cancer) plays an important role in chromosome segregation by interacting with a subset of checkpoint proteins that survey proper chromosome alignment and bipolar spindle attachment. In order to disrupt mitotic progression of tumor cell lines, we have used retrovirus and adenovirus vectors that inhibit Hec1 synthesis. Vector-expressed short hairpin RNAs (shRNAs) caused very efficient depletion of the target protein, cellular arrest and considerable mitotic catastrophe induction 96 h post infection in human cervix-adenocarcinoma (HeLa) and glioblastoma (U-373-MG) cell lines. Furthermore, adenocarcinomas induced in the flanks of nude mice show significant reduction in size compared with control when treated with either Hec1-shRNA retroviruses or adenoviruses. These results indicate that depletion of Hec1 could be used as a new strategy to block the dividing cell, and therefore against cancer.
Introduction
The recent discovery and characterization of RNA interference (RNAi) now provides us with a new tool for gene inactivation [1] [2] [3] and cancer gene therapy. 4 The basic mechanism of RNAi starts with a long doublestranded RNA (dsRNA) that is processed into small interfering RNAs (siRNAs) of about 21 nt. 5 These siRNAs mediate the suppression of the complementary mRNA through a phylogenetically conserved cellular pathway. 6 In mammalian cells, an RNAi response can be triggered by viral expression vectors that direct the synthesis of siRNA-like transcripts known as short hairpin interfering RNAs (shRNAs). 7 Stable expression of these shRNAs mediates persistent knockdown of target gene product over long periods of time. [8] [9] [10] Therefore, RNAi technology helps us to discover in cancer cells essential genes for viability that can then be used as targets for suicide induction.
A replicated chromosome possesses two discrete, complex, dynamic, macromolecular assemblies, known as kinetochores, which are positioned on opposite sides of the primary constriction of the chromosome. The correct segregation of chromosomes during the M phase is under the control of numerous proteins and protein subcomplex localized to kinetochores, which monitor the accuracy of this process.
11 Hec1, our choice as the therapeutic gene, plays an essential role in chromosome segregation; it localizes to kinetochores throughout mitosis and interacts with several proteins that modulate the G 2 /M phase of the cell cycle. RNAi technology was used to identify components of the conserved essential kinetochore protein family hMis12 complex (Mis12 in Schizosaccharomyces pombe) finding that Hec1 is one of the nine proteins that binds to hMis12. 12 HsSgt1 (homologue to the budding yeast Sgt1) is another protein required for human kinetochore assembly. RNA interferencemediated depletion of Sgt1 prevents Hec1 localization to mitotic kinetochores. 13 Although the exact function of Hec1 is unknown, the protein is essential for kinetochore-microtubule formation, is the yeast Ndc80 homologue 14 and interacts with three of the checkpoint proteins (Mps1, Mad1 and Mad2) that modulate metaphase progression. Hec1 depletion by siRNA was also used to establish the functional significance of these interactions. Hec1 is required for the kinetochore association of Mps1, and both Hec1 and Mps1 recruit Mad1/Mad2 complex to kinetochores. 15, 16 Also, depletion of Nuf2 and Hec1 by RNAi showed that both proteins are required for binding and retention of the checkpoint proteins Mad1 and Mad2 to kinetochores. 17 The knowledge that inactivation of Hec1 either by genetic deletion or antibody neutralization leads to severe and lethal disruption of mitotic progression 15, 18 prompted us to explore the possibility of using RNAi to cleave Hec1 mRNA, in an attempt to block division in cancer cells. It is therefore predictable that any interference with Hec1 function will result in cell arrest and mitotic catastrophe. We report here that inhibition of over 85% of Hec1 can be achieved in human cancer cell lines using retroviral interference vectors, leading to cell arrest and apoptosis in cultures. In experimental animals, tumors induced in the flanks of nude mice treated with anti-Hec1 retroviral producer cells or with concentrated anti-Hec1 retrovirus show a significant growth delay. To a lesser extent, purified adenovirus expressing antiHec1-shRNAs are also able to interfere with tumor growth in nude mice.
Results

Suppression of Hec1 protein levels in HeLa and U-373-MG cells by RNAi
We designed and constructed three retroviral vectors carrying the DNA to be transcribed into a shRNA against Hec1-mRNA (pRiHec1). The retroviral plasmids were used to transfect human amphotropic Phoenix packaging cells, and the supernatants containing retrovirus (retro RNAi Hec1 or empty retro) were used to infect U-373-MG and HeLa cells. The presence of retroviral DNA within the cellular genome was confirmed by PCR (data not shown) and by puromycin selection. At 96 h after viral infection, cells were harvested and Hec1 protein levels were analyzed by Western blotting. Of the three vectors tested, only one gave rise to over 80% inhibition of Hec1, while the others had marginal effects on protein concentration (data not shown). Inhibition values of 86% for HeLa cells and 91% for U-373-MG are shown in Figure 1a . Control empty retroviral vector (without the shRNA coding DNA) did not show any significant level of Hec1 reduction. In addition, suppression of Hec1 did not cause p53 upregulation (data not shown).
Hec1 can be visualized by immunofluorescence in empty retro-infected cells, but not in retro-RNAi Hec1-infected cells 96 h after viral infection (Figure 1b) 
Cellular effects of Hec1 RNAi inhibition
Cell cycle analysis by flow cytometry showed that the percentage of cells with 4N DNA content increases in Hec1-depleted cells ( Figure 2a ). This is consistent with observations previously made using transient siRNA against Hec1 in HeLa cells. 15 We have also measured the state of cyclin B1 in cells arrested by anti-Hec1-shRNA. Cyclins B (B1, B2 and B3) associated with cyclindependent kinase (CDK1) mark the end of the S phase and regulate G 2 /M transition and are degraded by the anaphase-promoting complex (APC). As expected, levels of cyclin B1 are higher in HeLa (26%) and U-373-MG (68%) cells expressing anti-Hec1-shRNA than in those cells infected with the empty version of retrovirus (Figure 2b ), indicating that cells are not able to pass through mitosis.
Apoptosis was measured in HeLa and U-373-MG cells expressing RNAi against Hec1 using an annexin V kit by direct counting of a minimum of 700 living cells at random (Figure 2c ). Values up to 52% in HeLa and 71% in U-373-MG of apoptosis and mitotic catastrophe (also known as mitotic cell death) were observed at 96 h post infection ( Figure 2d ).
Suppression of tumor formation in nude mice
The antitumoral activity of the retroviral vector carrying Hec1 RNAi sequence was assessed in nude mice xenografts. We infected HeLa cells with retro RNAi Hec1 having titers of 1. Figure 3c ) or antiHec1 isolated retrovirus particles (n ¼ 5, in two doses of 2 Â 10 6 concentrated retroviral particles each time, Figure  3d ). The right-side flanks were treated with the same amount of producer cells of empty retroviral particles or the empty retroviral particles as a control. In both cases again, there was a significant delay in growth on the Hec1-shRNA-treated left-side tumors. In order to show that Hec1-shRNA retroviruses downregulate Hec1 specifically, we analyzed xenograft proteins 5 days 
Discussion
In the present study, we tested the possibility of using RNA interference as a therapeutic agent against human cancer. The most common property of neoplastic cells is the uncontrolled proliferation that accompanies the transition from adult quiescent tissues to a tumoral mass within a fully differentiated adult organ. To ensure proper progression through the cell cycle, cells have developed a series of checkpoints that prevent them from entering into a new phase until they have successfully completed the previous one. We have chosen a protein required for retention of Mad1/Mad2 checkpoint complex to kinetochores to be targeted by RNAi: Hec1, contributing to control spindle formation and the correct segregation of chromosomes during the M phase of cell cycle. 15 It was hypothesized that inhibition of Hec1 would have severe effects on cell division. To obtain stable rather than transient expression of the RNAi, we have expressed shRNA from DNA-based retroviral vector, which infects dividing cells, 19 avoiding neighboring quiescent normal cells. The system is extremely safe for nondividing cells, not only because they will not be infected by retrovirus Moloney type but also because it is likely that those quiescent cells would not be actively expressing Hec1.
Our results demonstrate that RNAi can effectively downregulate to lethal levels Hec1 in HeLa and U-373-MG cells. At 4 days after retroviral infections, 86 and 91% inhibition of Hec1 in adenocarcinoma and glioblastoma cells, respectively, can cause 52 and 71% p53-independent cell death in those cells. We believe that the lethal effect of Hec1 is due to mitotic catastrophe induction 20 and genetic instability 21 since HeLa cells infected with retro RNAi Hec1 have higher levels of mitotic index than the control and the immunofluoresce images suggest a prometaphase or early metaphase arrest. We have also seen an increase in polyploid tumor cells after RNAi treatment and, although this sole fact does not abolish their proliferative capacity, these cells tend to have a longer cell cycle and smaller probability of undergoing further mitosis. 22 Many studies have described notable success in provoking cancer cell death in culture by siRNA treatments, [23] [24] [25] [26] [27] [28] but still very few are complemented with the eradication of well-developed tumors in experimental animals, a necessary step before using this technology in human trials. We have used the two main gene therapy vectors (retroviruses and adenoviruses) to evaluate the therapeutic response of shRNA treatment against Hec1 in vivo. Retroviruses are very efficient entering a wide range of hosts, including human cells, and will only integrate into replicating cells providing a very useful characteristic to target the neoplastic ones. The main drawback of retroviruses as vectors is the low titers produced by the retroviral packaging cells (B10 5 CFU per milliliter of culture). Adenoviruses as vectors are not free from problems: the genome size is too large to manipulate easily (36 kb) and they do not distinguish between quiescent and dividing cells. This last characteristic has been circumvented in the present study by choosing a target gene that is presumably only active in dividing cells. Also, adenoviruses are recognized to activate the immune system in immunocompetent animals when employed for somatic gene therapy in general; 29 nevertheless this response would be a desirable adjuvant effect for the cancer therapies. In our hands, adenoviral-based shRNA-producing vectors do not perform better in cell-cultured cells or in vivo than retroviral shRNAs delivery systems. In cell culture, we only achieve a maximum of 68% Hec1 inhibition in HeLa cells and 60% in U-373-MG, respectively, while retroviral-based vectors reach even 91% in the glioblastoma cells. This tendency is confirmed in experimental animals where, again, the therapeutic effect of retroviral vectors is slightly better than that of adenoviruses, despite a considerably higher titer of the latter. The promoters controlling shRNA expression in both systems are different, while in retroviruses shRNA transcription is driven adequately by the Pol III H1; in adenoviruses, the RNA Pol II promoter from cytomegalovirus (CMV) is the transcriptional driving force. Both vectors carry the same anti-Hec1 sequence: we may speculate that the difference in the protein knockdown could be attributed to different expression of shRNA levels motivated by the respective promoters. Indeed, a recent report 30 shows that the protein knockdown levels by RNAi is higher using H1 or U6 than the CMV promoter. Nevertheless, the authors achieve good repression levels with plasmid constructs carrying a variation of shRNA that mimic human micro-RNA (miR-30) under control of the CMV promoter.
This study has shown that Hec1 can be depleted very efficiently in a glioblastoma and adenocarcinoma human cell lines by shRNA expressed from a DNA-based retroviral or adenoviral vector. The inhibition affects their ability to grow (HeLa and U-373-MG) and develop tumors in nude mice (HeLa).
One advantage of using shRNAs as therapeutic agents is that their small size makes it possible to include more than one RNAi into a single vector that could inhibit multiple pathways simultaneously. 31 Loss of checkpoint functions in some cancer cells is considered to be associated with their sensitivity to antineoplastic treatments such as chemotherapy and radiation. Therefore, RNA interference vectors could be used in combination with other classical anticancer therapies to reinforce the therapeutic effect. Out of the many genetic alterations present in most human cancer cells, we can identify, through the use of this kind of technology, the most effective mRNA targets against each type of human cancer. Neoplastic cells unable to replace the interfered protein function would die, indicating the potency of RNAi as a new strategy for cancer therapy.
Materials and methods
Retrovirus vector construction
We have followed previously described methods 8, 9 with some modifications to generate pRetro-RNAi-Hec1 (pRiHec1) constructs from pRetro-Super. Specifically, Hec1 RNA interference as cancer therapy EN Gurzov and M Izquierdo the vector was digested with BglII and XhoI and the annealed oligos were ligated into the vector. Three RNAi retrovirus vectors were tested against levels of Hec1 in HeLa and U-373-MG cells; the synthetic DNA sequences corresponding to the shRNAs for Hec1 were selected from GenBank accession number NM_006101 (AATTAA TAAAGCCCTAAAT, ATCAAGGACCCGAGACCAC and GTTCAAAAGCTGGATGATC).
Cell culture, transfection and infection
Cells (HeLa, U-373-MG, 293T and Phoenix Ampho cells) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum. Vectors pRiHec1 or pRetro-Super were transfected in Phoenix Ampho cells using Lipofetamine-Plus (Life Technologies, Inc.), following the protocols provided by the manufactures. At 48 h after transfection, the cell culture medium was filtered though a 0.45 mm filter, and the viral supernatant was used for the infection of cells after the addition of 4 mg/ml of polybrene. Cells were infected overnight and allowed to recover for 24 h with fresh medium. Infected cells were selected with puromycin 1-2 mg/ml for 24 h. Titers were estimated by infecting NIH-3T3 cells as described previously. 32 For virus concentration, we use Beckman Konical tubes (ref. 358126). Then, 4 ml of sucrose 20% in water was added in the bottom of the tube and was filled up to the top with retroviral medium filtered (0.45 mm filter) and centrifuged at 26 k r.p.m. for 90 min. The supernatant was discarded and the pellet was resuspended in serumfree medium.
Adenovirus production
The recombinant adenovirus adeno RNAi Hec1 or empty adeno were produced and concentrated following manufacturer's recommendations (pSilencer adeno 1.0 CMV System kit, Ambion).
Western blotting
At 96 h after transfection, cells were lysed on ice in lysis buffer (50 mM Tris-HCl (pH 7.5), 300 mM NaCl, 0.5% Triton X-100, 1 mM EDTA and protease inhibitor). Cellular debris was centrifuged for 10 min at 14 000 g. Equal amounts of proteins, as determined by the BCA protein microassay (Biorad), were resolved by sodium dodecyl sulfate-polyacrilamide gel electrophoresis (SDS-PAGE) and electroblotted onto nitrocellulose membranes. For immunoblotting, membranes were blocked in PBS-0.1% Tween20 with 10% milk; the blots were then incubated with the appropriate antibodies. Primary antibodies used were rabbit anti-cyclin B1 (Santa Cruz Biotechnology cat. sc-594, 1/200), rabbit anti-Hec1 (J Kilmartin (14), 1/500), rabbit anti-actin (SIGMA, 1/200) and mouse anti-a-tubulin (SIGMA). The protein was detected by chemoluminescence, using Hp-conjugated antibody (DAKO, 1/5000).
Quantification of immunoreactivity was performed by using a GS-710 Calibrated Imaging densitometer scanner controller by Quantity One PC software from Bio-Rad (Hercules, CA, USA). In all cases, the average intensity value of the pixels in a background-selected region was calculated and was subtracted from each pixel in the samples. The densitometry values obtained in the linear range of detection with these antibodies were normalized with respect to the values obtained with an antia-tubulin or anti-actin antibody to correct for any deviation in loaded amounts of protein.
Immunofluorescence
After 96 h in the presence of puromycin, infected cells were washed with PBS and fixed in methanol at À201C for 5 min, and then blocked in PBS plus 1% BSA. This buffer was used in subsequent washing and antibody incubation steps. Cells were then incubated for 1 h at 371C with anti-Hec1 or anti-Ki67 nuclear antigen (Novo) and a mouse anti-a-tubulin (SIGMA) antibody, and incubated for a second hour with an anti-rabbit fluorescein and antimouse Texas red-conjugated secondary antibody (Amersham). We have used DAPI (Calbiochem) for DNA staining. After hybridization and the subsequent washing steps, the cells were mounted with Fluoromount-G (Southern Biotechnology Associates, Inc.). Microscopy was performed on a vertical Axioskop2 plus Microscope (Zeiss).
Fluorescence-activated cell sorter (FACS) analysis
Cells were harvested by trypsin digestion, washed with cold PBS and resuspended in 75% ethanol at 41C for at least 8 h. The fixed cells were collected by brief centrifugation and resupended in PBS containing propidium iodide (5 mg/ml)/RNase A (25 mg/ml). After incubation for 30 min at room temperature, samples were subjected to FACS.
Apoptosis (mitotic catastrophe) assay
Apoptosis was measured using an apoptosis detection kit (Sigma, cat. APO-AC). Briefly, phosphatidylserine transport to the external plasma membrane during the onset of apoptosis is stained with annexin V (red cells). The apoptosis index was defined by the percentage of annexinstained cells among the total live cells (green). More than 700 cells were randomly counted for each sample.
Tumor xenografts in nude mice
All animal experiments were performed in compliance with the UK Coordinating Committee on Cancer Research guidelines for the Welfare of Animals in Experimental Neoplasia, and we have adhered to the standards of our institution bioethics and bio-security committees and to the 'Protection of animals used for scientific purposes' (Protecció n de los animales utilizados con fines científicos; Spanish National Royal Decree RD 223/88). Tumor size (length, width and height) was measured weekly by caliper and the tumor volume was calculated (p/6 Â (length Â width Â height)). Survival of 6-week female athymic nude mice used was defined as the time until the tumor reached 10% of the mouse's weight or 5 weeks after the tumor injection; past this point the mice were euthanized. The difference in tumor volume between treated groups was compared for statistic significance using the paired t-test.
Abbreviations
RNAi, RNA interference; dsRNA, double-stranded RNA; shRNAs, short hairpin RNAs; RISC, RNA-induced silencing complex; Hec1, highly expressed in cancer; pRiHec1, retroviral plasmid carrying the DNA corresponding to Hec1-shRNA.
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